Nonalcoholic fatty liver disease

A challenge for pediatricians

Valerio Nobili, Naim Alkhouri, Anna Alisi, Claudia Della Corte, Emer Fitzpatrick, Massimiliano Raponi, Anil Dhawan

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is considered the most common form of chronic liver disease in children. Several factors contribute to NAFLD development, including race/ethnicity, genetic factors, environmental exposures, and alterations in the gut microbiome. The histologic spectrum of NAFLD ranges from simple steatosis to the more aggressive nonalcoholic steatohepatitis (NASH). Fibrosis and eventually cirrhosis can develop from NAFLD during childhood. Diagnosing advanced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable, noninvasive markers of disease severity. The mainstay of treatment for NAFLD remains lifestyle modifications and weight loss. Probiotics and ω-3 fatty acids may ameliorate disease progression. Recent data have suggested that vitamin Emay be considered as a NASH-specific therapy in children, and there are several ongoing human studies evaluating different therapeutic targets for NAFLD.We provide an up-to-date review of the risk factors, diagnosis, and treatment to manage this common disease in children.

Original languageEnglish
Pages (from-to)170-176
Number of pages7
JournalJAMA Pediatrics
Volume169
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Fibrosis
Pediatricians
Non-alcoholic Fatty Liver Disease
Liver
Environmental Exposure
Probiotics
Therapeutics
Vitamins
Disease Progression
Life Style
Liver Diseases
Weight Loss
Chronic Disease
Fatty Acids
Biopsy
Gastrointestinal Microbiome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Nonalcoholic fatty liver disease : A challenge for pediatricians. / Nobili, Valerio; Alkhouri, Naim; Alisi, Anna; Della Corte, Claudia; Fitzpatrick, Emer; Raponi, Massimiliano; Dhawan, Anil.

In: JAMA Pediatrics, Vol. 169, No. 2, 01.02.2015, p. 170-176.

Research output: Contribution to journalArticle

@article{c7237dc6b77b440c88e355e6997a50c2,
title = "Nonalcoholic fatty liver disease: A challenge for pediatricians",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is considered the most common form of chronic liver disease in children. Several factors contribute to NAFLD development, including race/ethnicity, genetic factors, environmental exposures, and alterations in the gut microbiome. The histologic spectrum of NAFLD ranges from simple steatosis to the more aggressive nonalcoholic steatohepatitis (NASH). Fibrosis and eventually cirrhosis can develop from NAFLD during childhood. Diagnosing advanced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable, noninvasive markers of disease severity. The mainstay of treatment for NAFLD remains lifestyle modifications and weight loss. Probiotics and ω-3 fatty acids may ameliorate disease progression. Recent data have suggested that vitamin Emay be considered as a NASH-specific therapy in children, and there are several ongoing human studies evaluating different therapeutic targets for NAFLD.We provide an up-to-date review of the risk factors, diagnosis, and treatment to manage this common disease in children.",
author = "Valerio Nobili and Naim Alkhouri and Anna Alisi and {Della Corte}, Claudia and Emer Fitzpatrick and Massimiliano Raponi and Anil Dhawan",
year = "2015",
month = "2",
day = "1",
doi = "10.1001/jamapediatrics.2014.2702",
language = "English",
volume = "169",
pages = "170--176",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease

T2 - A challenge for pediatricians

AU - Nobili, Valerio

AU - Alkhouri, Naim

AU - Alisi, Anna

AU - Della Corte, Claudia

AU - Fitzpatrick, Emer

AU - Raponi, Massimiliano

AU - Dhawan, Anil

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is considered the most common form of chronic liver disease in children. Several factors contribute to NAFLD development, including race/ethnicity, genetic factors, environmental exposures, and alterations in the gut microbiome. The histologic spectrum of NAFLD ranges from simple steatosis to the more aggressive nonalcoholic steatohepatitis (NASH). Fibrosis and eventually cirrhosis can develop from NAFLD during childhood. Diagnosing advanced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable, noninvasive markers of disease severity. The mainstay of treatment for NAFLD remains lifestyle modifications and weight loss. Probiotics and ω-3 fatty acids may ameliorate disease progression. Recent data have suggested that vitamin Emay be considered as a NASH-specific therapy in children, and there are several ongoing human studies evaluating different therapeutic targets for NAFLD.We provide an up-to-date review of the risk factors, diagnosis, and treatment to manage this common disease in children.

AB - Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is considered the most common form of chronic liver disease in children. Several factors contribute to NAFLD development, including race/ethnicity, genetic factors, environmental exposures, and alterations in the gut microbiome. The histologic spectrum of NAFLD ranges from simple steatosis to the more aggressive nonalcoholic steatohepatitis (NASH). Fibrosis and eventually cirrhosis can develop from NAFLD during childhood. Diagnosing advanced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable, noninvasive markers of disease severity. The mainstay of treatment for NAFLD remains lifestyle modifications and weight loss. Probiotics and ω-3 fatty acids may ameliorate disease progression. Recent data have suggested that vitamin Emay be considered as a NASH-specific therapy in children, and there are several ongoing human studies evaluating different therapeutic targets for NAFLD.We provide an up-to-date review of the risk factors, diagnosis, and treatment to manage this common disease in children.

UR - http://www.scopus.com/inward/record.url?scp=84964310794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964310794&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2014.2702

DO - 10.1001/jamapediatrics.2014.2702

M3 - Article

VL - 169

SP - 170

EP - 176

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 2

ER -